FECAL CALPROTECTIN TEST MARKET ANALYSIS

Fecal Calprotectin Test Market, By Assay Type (Enzyme Linked Immunosorbent Assay (ELISA), Enzyme Fluoroimmunoassay, and Quantitative Immune-Chromatography), By Indication (Inflammatory Bowel Disease (IBD) Diagnosis, Colorectal Cancer, Celiac Disease, and others), By End User (Hospitals, Diagnostic Laboratories, Academic and Research Institutes, and others), , By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments

New product launches

In June 2022, Meridian Bioscience, Inc., a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products, announced the launch of two new sample-specific master mixes, Lyo-Ready Direct DNA qPCR Stool Mix, and Lyo-Ready™ Direct RNA/DNA qPCR Stool Mix. These two master mixes improve the molecular detection of DNA and RNA from crude fecal specimens while allowing room-temperature stabilization of diagnostic assays.

Acquisition and partnerships

In 2022, Meridian Bioscience acquired Calpro, a Norwegian company that develops and manufactures calprotectin-based diagnostic tests. This acquisition helped Meridian Bioscience expand its presence in the fecal calprotectin test market and to offer a wider range of products to its customers.
In 2020, Bio-Rad Laboratories, a company focused in developing and manufacturing various products associated with healthcare; acquired Enzo Biochem, a company that develops and manufactures diagnostic tests. This acquisition helped Bio-Rad Laboratories expand its presence in the fecal calprotectin test market and offer a wider range of products to its customers.

Fecal Calprotectin Test Market Report Snapshots